Name: VRDN Cash Flow - Viridian Therapeutics, Inc.de Operating Cash & FCF | Ledgeburg
Creator: Ledgeburg
License: https://creativecommons.org/licenses/by/4.0/
Keywords: Operating Cash Flow, Investing Cash Flow, Financing Cash Flow, Capital Expenditures, Free Cash Flow, Dividends Paid, Stock Buybacks, Net Change in Cash

JavaScript is disabled. Some features may not work properly. For the best experience, please enable JavaScript in your browser.

VRDN - Viridian Therapeutics, Inc.de

USD | NASDAQ | Healthcare

VRDN Cash Flow - Viridian Therapeutics, Inc.de Operating Cash & FCF | Ledgeburg

(in millions of USD)	Q1 FY 26	Q4 FY 25	Q3 FY 25	Q2 FY 25	Q1 FY 25	Q4 FY 24	Q3 FY 24	Q2 FY 24	Q1 FY 24	Q4 FY 23	Q3 FY 23	Q2 FY 23	Q1 FY 23	Q4 FY 22	Q3 FY 22	Q2 FY 22	Q1 FY 22	Q4 FY 21	Q3 FY 21	Q2 FY 21	Q1 FY 21	Q4 FY 20	Q3 FY 20	Q2 FY 20	Q1 FY 20	Q4 FY 19	Q3 FY 19	Q2 FY 19	Q1 FY 19	Q4 FY 18	Q3 FY 18	Q2 FY 18	Q1 FY 18	Q4 FY 17	Q3 FY 17	Q2 FY 17	Q1 FY 17	Q4 FY 16	Q3 FY 16	Q2 FY 16
Net Income
Net Income	(104.9)	(120.4)	(34.6)	(100.7)	(86.9)	(79.7)	(76.7)	(65.0)	(48.5)	(66.9)	(47.7)	(55.1)	(68.2)	(45.8)	(28.9)	(29.5)

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

(in millions of USD)	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013
Net Income
Net Income	(360.6)	(342.6)	(269.9)	(237.7)	(129.9)	(79.4)	(110.7)	(41.9)	(32.7)	(26.5)	(17.3)	(11.3)	(7.9)	(2.2)
Cash From Operating Activities
Depreciation & Amortization	-	0.5	0.5	0.5	0.3	0.1	0.2	0.3	0.3	0.3	0.3	0.2	0.1	0.1
Cash From Investing Activities
Capital Expenditures	-	0.5	0.5	0.9	0.8	0.3	0.0	0.1	0.4	0.2	0.3	0.1	0.3	0.0
Cash From Financing Activities
Debt Issued	-	28.9	0.0	15.0	5.0	-	-	-	-	-	-	-	-	-
Debt Repaid
Change In Cash & Equivalents
Effects Of Exchange Rate Changes	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow
Free Cash Flow	-	(276.9)	(232.8)	(185.1)	(94.6)	(54.9)	(29.8)	(36.1)	(27.3)	(28.4)	(15.0)	(7.0)	(2.5)	(1.2)
Free Cash Flow To Equity

Source: SEC EDGAR company filings. Figures as reported (US GAAP)

Change In Cash & Equivalents
Effects Of Exchange Rate Changes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Change In Cash	(36.0)	-	-	-	16.6	-	-	-	(11.2)	-	-	-	(67.1)	-	-	-	(11.4)	-
Cash Beginning Of Period	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash End Of Period	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Free Cash Flow
Free Cash Flow	(119.7)	-	-	-	(92.7)	-	-	-	(45.2)	-	-	-	(62.1)	-	-	-	(21.2)	-	-	-	(11.6)	-	-	-	(8.5)	-	-	-	(11.8)	-	-	-	(7.5)	-	-	-	(8.2)	-	-	-
Free Cash Flow To Equity	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Cash Flow Statement

Cash Flow Statement

Cash From Operating Activities
Depreciation & Amortization	0.1	-	-	-	0.1	-	-	-	0.1	-	-	-	0.1	-	-	-	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1
Amortization Of Intangibles	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Stock-Based Compensation	13.4	12.0	11.3	10.8	10.2	9.0	8.7	11.8	12.7	26.0	13.6	12.3	15.2	5.3	4.9	4.9	4.7
Deffered Income Tax	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Asset Impairments	-	-	-	-	0.0	-	-	-	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gains & Losses On Investments	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change In Accounts Receivable	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change In Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change In Accounts Payable	4.6	-	-	-	1.8	-	-	-	0.5	-	-	-	(6.6)	-	-	-	0.0
Change In Other Working Capital	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Operating Activities	(0.2)	-	-	-	0.0	-	-	-	0.0	-	-	-	(0.0)	-	-	-	0.0
Cash From Operating Activities	(119.7)	-	-	-	(92.7)	-	-	-	(45.2)	-	-	-	(62.0)	-	-

Cash From Investing Activities
Capital Expenditures	0.0	-	-	-	0.1	-	-	-	0.0	-	-	-	0.1	-	-	-	0.2	-	-	-	0.0	-	-	-	0.0	-	-	-	0.0	-	-	-	0.1	-	-	-	0.0	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Divestitures	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase Of Investments	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Sales Of Investments	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Investing Activities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash From Investing Activities	77.3	-	-	-	100.1	-	-	-	(143.0)	-	-	-	(13.3)	-	-